Companies Bausch Health Companies Inc.
Bausch Health Companies (BHC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Bausch Health Companies Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers54th pct.Of 13 peer CEOs
CEO pay, last three years
- $15,878,578FY2023
- $16,239,133FY2024
- $16,877,326FY2025
CEO total pay was $16,877,326 in fiscal 2025, up from $16,239,133 in fiscal 2024.
FY2025: salary $1,236,000 · bonus $250,000 · stock awards $13,032,562 · option awards $0
Executives and directors
Aimee Lenar · EVPJean-Jacques Charhon · CFOSeana Carson · General CounselThomas Appio · CEOAmy B. Wechsler · Independent DirectorBrett M. Icahn · Former director (through FY2025)Christian A. Garcia · Independent DirectorEiry W. Roberts · Independent DirectorFrank D. Lee · Independent DirectorJohn A. Paulson · Chair of the BoardMichael Goettler · Independent DirectorRichard C. Mulligan · Independent DirectorRobert N. Power · Independent DirectorSandra Leung · Independent DirectorSarah B. Kavanagh · Independent DirectorSteven D. Miller · Former director (through FY2025)
Frequently asked questions
Who was the highest-paid executive at Bausch Health Companies Inc. in fiscal 2025?
As disclosed, Thomas Appio (Chief Executive Officer) was the highest-paid executive at Bausch Health Companies Inc. in fiscal 2025, with total compensation of $16,877,326.
How does Bausch Health Companies Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Thomas Appio's total compensation ranked at the 54th percentile of Bausch Health Companies Inc.'s disclosed peer group.
What is Bausch Health Companies Inc.'s CEO-to-median employee pay ratio?
As disclosed, Bausch Health Companies Inc.'s CEO-to-median employee pay ratio was 401:1.
How did shareholders vote on Bausch Health Companies Inc.'s executive compensation?
As disclosed, 95.18% of shareholders supported Bausch Health Companies Inc.'s executive compensation in the latest say-on-pay vote.
How much does Bausch Health Companies Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Bausch Health Companies Inc. reported total board compensation of $4,913,551 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Thomas Appio | $1,236,000 | $250,000 | $13,032,562 | $0 | $2,336,000 | $0 | $22,764 | $16,877,326 |
| Chief Executive Officer | ||||||||
| Jean-Jacques Charhon | 700,000 | — | 3,517,941 | 0 | 661,500 | 0 | 25,634 | 4,905,075 |
| Executive Vice President, Chief Financial Officer | ||||||||
| Seana Carson | 642,222 | 50,000 | 2,931,613 | — | 614,250 | 0 | 23,522 | 4,261,607 |
| Executive Vice President, General Counsel | ||||||||
| Aimee Lenar | 650,000 | 0 | 1,958,861 | 0 | 628,880 | 0 | 26,750 | 3,264,491 |
| Executive Vice President, US Pharma | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Thomas Appio | $16,877,326 | $16,239,133 | $15,878,578 | ↑ +638,193 |
| Jean-Jacques Charhon | 4,905,075 | 4,267,087 | — | ↑ +637,988 |
| Seana Carson | 4,261,607 | 3,972,479 | 3,157,817 | ↑ +289,128 |
| Aimee Lenar | 3,264,491 | 1,986,437 | — | ↑ +1,278,054 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Bausch Health's compensation philosophy is designed to attract, retain, and motivate talented executives, including our NEOs, who champion our purpose of enriching lives through our relentless drive to improve healthcare outcomes for our patients and customers. Our compensation program is designed to retain our critical leaders, link executive compensation to long-term business performance, and provide compensation opportunities that are competitive as compared to our peers and align the interests of our executives with those of our shareholders.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Thomas Appio | PSU | 2025-02-26 | 357,426 | 953,137 | — | 1,906,274 | $8,139,789 |
| Jean-Jacques Charhon | RSU | 2025-02-26 | — | — | 216,622 | — | 1,667,989 |
| Seana Carson | PSU | 2025-02-26 | 67,694 | 180,518 | — | 361,036 | 1,541,624 |
| Aimee Lenar | PSU | 2025-02-26 | 40,617 | 108,311 | — | 216,622 | 924,977 |
| Seana Carson | RSU | 2025-02-26 | — | — | 180,518 | — | 1,389,989 |
| Thomas Appio | RSU | 2025-02-26 | — | — | 635,425 | — | 4,892,773 |
| Jean-Jacques Charhon | PSU | 2025-02-26 | 81,233 | 216,622 | — | 433,244 | 1,849,952 |
| Aimee Lenar | RSU | 2025-02-26 | — | — | 108,311 | — | 833,995 |
| Aimee Lenar | RSU | 2025-07-17 | — | — | 30,847 | — | 199,889 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Thomas Appio | $4,892,773 | $8,139,789 | $0 | 62.5% |
| Jean-Jacques Charhon | 1,667,989 | 1,849,952 | 0 | 52.6% |
| Seana Carson | 1,389,989 | 1,541,624 | 0 | 52.6% |
| Aimee Lenar | 1,033,884 | 924,977 | 0 | 47.2% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Seana Carson | Option | 3,996 | 23.92 | — |
| Seana Carson | Option | 4,246 | 23.16 | — |
| Seana Carson | Option | 11,360 | 32.56 | — |
| Seana Carson | Option | 18,115 | 24.77 | — |
| Seana Carson | Option | 27,373 | 9.25 | — |
| Thomas Appio | Option | 30,174 | 14.38 | — |
| Aimee Lenar | RSU | 30,847 | — | 214,387 |
| Seana Carson | RSU | 31,707 | — | 220,364 |
| Thomas Appio | Option | 47,151 | 32.56 | — |
| Thomas Appio | RSU | 55,555 | — | 948,879 |
| Thomas Appio | Option | 62,004 | 23.16 | — |
| Thomas Appio | Option | 65,923 | 15.32 | — |
| Thomas Appio | Option | 81,873 | 24.77 | — |
| Aimee Lenar | RSU | 96,235 | — | 668,833 |
| Seana Carson | RSU | 98,358 | — | 683,588 |
| Aimee Lenar | RSU | 108,311 | — | 752,761 |
| Seana Carson | Option | 124,372 | 24.17 | — |
| Seana Carson | RSU | 137,923 | — | 958,562 |
| Thomas Appio | RSU | 174,385 | — | 1,211,976 |
| Seana Carson | RSU | 180,518 | — | 1,254,600 |
| Jean-Jacques Charhon | RSU | 199,225 | — | 1,384,614 |
| Aimee Lenar | RSU | 216,622 | — | 1,505,522 |
| Jean-Jacques Charhon | RSU | 216,622 | — | 1,505,523 |
| Seana Carson | RSU | 295,072 | — | 2,050,750 |
| Thomas Appio | RSU | 346,219 | — | 2,406,222 |
| Seana Carson | RSU | 361,036 | — | 2,509,200 |
| Jean-Jacques Charhon | RSU | 433,244 | — | 3,011,046 |
| Thomas Appio | Option | 565,330 | 24.17 | — |
| Jean-Jacques Charhon | RSU | 597,676 | — | 4,153,848 |
| Thomas Appio | RSU | 635,425 | — | 4,416,204 |
| Thomas Appio | RSU | 1,137,863 | — | 7,908,147 |
| Thomas Appio | RSU | 1,557,980 | — | 10,827,962 |
| Thomas Appio | RSU | 1,906,274 | — | 13,248,604 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John A. PaulsonIndependent · Board Chair | $21,875 | $783,730 | $0 | — | $0 | $805,605 |
| Sarah B. KavanaghIndependent · Audit and Risk Committee · Nominating and Corporate Governance Committee | 239,991 | 489,988 | 0 | — | 0 | 729,979 |
| Brett M. IcahnNot independent · Departed during FY | 62,192 | 562,312 | 0 | — | 0 | 624,504 |
| Robert N. PowerIndependent · Talent and Compensation Committee (Chair) · Nominating and Corporate Governance Committee | 142,680 | 250,000 | 0 | — | 0 | 392,680 |
| Frank D. LeeIndependent · Talent and Compensation Committee · Nominating and Corporate Governance Committee · Science and Technology Committee | 136,147 | 250,000 | 0 | — | 0 | 386,147 |
| Amy B. WechslerIndependent · Talent and Compensation Committee · Science and Technology Committee | 100,000 | 277,500 | 0 | — | 0 | 377,500 |
| Christian A. GarciaIndependent · Audit and Risk Committee (Chair) | 125,000 | 250,000 | 0 | — | 0 | 375,000 |
| Richard C. MulliganIndependent · Science and Technology Committee (Chair) · Not standing for re-election | 123,844 | 250,000 | 0 | — | 0 | 373,844 |
| Steven D. MillerNot independent · Departed during FY | 77,829 | 250,000 | 0 | — | 0 | 327,829 |
| Michael GoettlerIndependent · Science and Technology Committee · Talent and Compensation Committee · Newly elected | 56,676 | 204,110 | 0 | — | 0 | 260,786 |
| Sandra LeungIndependent · Audit and Risk Committee · Nominating and Corporate Governance Committee (Chair) · Newly elected | — | 259,677 | 0 | — | 0 | 259,677 |
| Thomas J. AppioEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Eiry W. RobertsIndependent · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $100,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 25,000 / 20,000 |
| Stock ownership guideline | $5 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,086,234 |
| Equity awards (grant-date value) | $3,827,317 |
| All other compensation | $0 |
| Total cost of the board | $4,913,551 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Bausch Health Companies as a peer
Companies that benchmark against BHC
5 companies name BHC as a compensation peer
The list of companies that name BHC as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ELAN Elanco Animal Health IncorporatedBIIB Biogen Inc.BMRN BioMarin Pharmaceutical Inc.INCY Incyte CorporationJAZZ Jazz Pharmaceuticals plcOGN Organon & Co.STE Steris plcTEVA Teva Pharmaceutical Industries LimitedUTHR United Therapeutics CorporationVTRS Viatris Inc.HOLX Hologic, Inc.PRGO Perrigo Company plcZBH Zimmer Biomet Holdings Inc.
Peer reciprocity
The companies Bausch Health Companies Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Incyte Corporation | 2025 | William Meury | $647,260 | $27,509,657 | $2,573,998 | $1,300,000 | $32,085,952 |
| 2 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 3 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 4 | Teva Pharmaceutical Industries Limited | 2025 | Richard Francis | 1,700,000 | 11,999,970 | 0 | 4,827,405 | 19,168,709 |
| 5 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 6 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 7 | Bausch Health Companies Inc. | 2025 | Thomas Appio | 1,236,000 | 13,032,562 | 0 | 2,336,000 | 16,877,326 |
| 8 | Zimmer Biomet Holdings Inc. | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 9 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 10 | Organon & Co. | 2025 | Kevin Ali | 1,088,462 | 10,251,989 | 3,249,999 | 0 | 15,813,296 |
| 11 | Viatris Inc. | 2025 | Scott Smith | 1,448,654 | 10,150,013 | 0 | 2,973,660 | 15,273,331 |
| 12 | Elanco Animal Health Incorporated | 2025 | Jeffrey Simmons | 1,200,000 | 9,000,000 | 3,000,004 | 1,700,400 | 14,925,756 |
| 13 | Steris plc | 2026 | Daniel Carestio | 1,095,707 | 4,333,951 | 4,334,251 | 1,725,007 | 11,508,522 |
| 14 | Perrigo Company plc | 2025 | Patrick Lockwood-Taylor | 1,223,333 | 6,990,564 | 0 | 687,250 | 9,042,603 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Bausch Health Companies Inc. | 126% | PSU 60 · RSU 40 | Yes — Relative Total Shareholder Return (rTSR) | Pay Governance |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Elanco Animal Health Incorporated | not disclosed | not disclosed | No | Willis Towers Watson |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Organon & Co. | 72% | PSU 50 · RSU 25 · Options 25 | Yes — Three-Year Relative TSR | Korn Ferry |
| Perrigo Company plc | 44.3% | PSU 70 · RSU 30 | Yes — Relative TSR (rTSR) | Frederic W. Cook & Company, Inc. |
| Steris plc | 125.1% | Option 50 · Restricted Stock 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Teva Pharmaceutical Industries Limited | not disclosed | PSU 70 · RSU 30 | No | Meridian |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
| Viatris Inc. | 136.72% | PSU 65 · RSU 35 | No | Meridian Compensation Partners, LLC |
| Zimmer Biomet Holdings Inc. | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-19 | 189,432,400 | 9,588,417 | 537,614 | 95.18% | Passed |
| 2024 | 2024-05-14 | 78,660,733 | 5,195,531 | 8,435,696 | 93.8% | Passed |
| 2023 | 2023-05-16 | 178,033,723 | 15,117,579 | 629,322 | 92.17% | Passed |
| 2022 | 2022-05-02 | 138,688,673 | 73,295,304 | 473,087 | 65.42% | Passed |
| 2021 | 2021-04-27 | 190,546,050 | 15,043,145 | 548,900 | 92.68% | Passed |
| 2020 | 2020-04-28 | 197,628,762 | 22,998,724 | 947,352 | 89.58% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-19 | 95.18%a |
| 2024 | 2024-05-14 | 93.8%b |
| 2023 | 2023-05-16 | 92.17%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 401 : 1 |
|---|---|
| CEO total compensation | $16,877,326 |
| Median employee compensation | $42,062 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Frank D. Lee | Director | 2026-05-19 | D | 24,456 | $5 | $132,796 | Common | Form 4 ↗ |
| Michael Goettler | Director | 2026-05-22 | A | 45,871 | 0 | 0 | Common | Form 4 ↗ |
| Sarah B. Kavanagh | Director | 2026-05-22 | A | 45,871 | 0 | 0 | Common | Form 4 ↗ |
| Frank D. Lee | Director | 2026-05-22 | A | 45,871 | 0 | 0 | Common | Form 4 ↗ |
| Robert N. Power | Director | 2026-05-22 | A | 45,871 | 0 | 0 | Common | Form 4 ↗ |
| Eiry W. Roberts | Director | 2026-05-22 | A | 45,871 | 0 | 0 | Common | Form 4 ↗ |
| John A. Paulson | Director | 2026-05-22 | A | 45,871 | 0 | 0 | Common | Form 4 ↗ |
| Amy B. Wechsler | Director | 2026-05-22 | A | 45,871 | 0 | 0 | Common | Form 4 ↗ |
| Sandra Leung | Director | 2026-05-22 | A | 45,871 | 0 | 0 | Common | Form 4 ↗ |
| Christian A. Garcia | Director | 2026-05-22 | A | 45,871 | 0 | 0 | Common | Form 4 ↗ |
| Sandra Leung | Director | 2026-06-30 | A | 6,845 | 5 | 33,746 | Common | Form 4 ↗ |
| Amy B. Wechsler | Director | 2026-06-30 | A | 1,394 | 5 | 6,872 | Common | Form 4 ↗ |
| John A. Paulson | Director | 2026-06-30 | A | 12,677 | 5 | 62,498 | Common | Form 4 ↗ |
| Frank D. Lee | SVP, Controller & CAO | 2026-07-14 | D | 3,125 | 5 | 14,844 | Common | Form 4 ↗ |
| Aimee Lenar | President, US Pharma | 2026-07-15 | D | 23,395 | 5 | 114,402 | Common | Form 4 ↗ |
| Aimee Lenar | President, US Pharma | 2026-07-17 | D | 5,260 | 5 | 25,406 | Common | Form 4 ↗ |
| Aimee Lenar | President, US Pharma | 2026-08-19 | D | 36,827 | 7 | 258,894 | Common | Form 4 ↗ |
| Sandra Leung | Director | 2026-09-30 | A | 5,789 | 6 | 33,750 | Common | Form 4 ↗ |
| John A. Paulson | Director | 2026-09-30 | A | 10,720 | 6 | 62,498 | Common | Form 4 ↗ |
| Amy B. Wechsler | Director | 2026-09-30 | A | 1,179 | 6 | 6,874 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (70 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Thomas Appio. DEF 14A, filed 2026-04-08. Section “2025 SUMMARY COMPENSATION TABLE” · page 54. As printed: 16,877,326. View filing ↗
- Section 01, Jean-Jacques Charhon. DEF 14A, filed 2026-04-08. Section “2025 SUMMARY COMPENSATION TABLE” · page 54. As printed: 4,905,075. View filing ↗
- Section 01, Seana Carson. DEF 14A, filed 2026-04-08. Section “2025 SUMMARY COMPENSATION TABLE” · page 54. As printed: 4,261,607. View filing ↗
- Section 01, Aimee Lenar. DEF 14A, filed 2026-04-08. Section “2025 SUMMARY COMPENSATION TABLE” · page 54. As printed: 3,264,491. View filing ↗
- Section 03, Thomas Appio PSU. DEF 14A, filed 2026-04-08. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jean-Jacques Charhon RSU. DEF 14A, filed 2026-04-08. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Seana Carson PSU. DEF 14A, filed 2026-04-08. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Aimee Lenar PSU. DEF 14A, filed 2026-04-08. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Seana Carson RSU. DEF 14A, filed 2026-04-08. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas Appio RSU. DEF 14A, filed 2026-04-08. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jean-Jacques Charhon PSU. DEF 14A, filed 2026-04-08. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Aimee Lenar RSU. DEF 14A, filed 2026-04-08. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Aimee Lenar RSU. DEF 14A, filed 2026-04-08. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-08. Section “CEO Pay Ratio”. As printed: 401 : 1. View filing ↗
- Section 08, John A. Paulson. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 805,605. View filing ↗
- Section 08, Sarah B. Kavanagh. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 729,979. View filing ↗
- Section 08, Brett M. Icahn. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 624,504. View filing ↗
- Section 08, Robert N. Power. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 392,680. View filing ↗
- Section 08, Frank D. Lee. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 386,147. View filing ↗
- Section 08, Amy B. Wechsler. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 377,500. View filing ↗
- Section 08, Christian A. Garcia. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 375,000. View filing ↗
- Section 08, Richard C. Mulligan. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 373,844. View filing ↗
- Section 08, Steven D. Miller. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 327,829. View filing ↗
- Section 08, Michael Goettler. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 260,786. View filing ↗
- Section 08, Sandra Leung. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 259,677. View filing ↗
- Section 08, Thomas J. Appio. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Eiry W. Roberts. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Frank D. Lee 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Goettler 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah B. Kavanagh 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank D. Lee 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert N. Power 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eiry W. Roberts 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John A. Paulson 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Amy B. Wechsler 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Leung 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christian A. Garcia 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Leung 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Amy B. Wechsler 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John A. Paulson 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank D. Lee 2026-07-14. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aimee Lenar 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aimee Lenar 2026-07-17. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aimee Lenar 2026-08-19. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Leung 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John A. Paulson 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Amy B. Wechsler 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-19. Item 5.07 · say-on-pay result. As reported: 95.18% (votes for as printed: 189,432,400). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-15. Item 5.07 · say-on-pay result. As reported: 93.8% (votes for as printed: 78,660,733). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-17. Item 5.07 · say-on-pay result. As reported: 92.17% (votes for as printed: 178,033,723). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 1,086,234 + equity 3,827,317 + all other 0 = 4,913,551, summed across the director compensation table rows.
- Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
- Biogen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. View filing ↗
- BioMarin Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. View filing ↗
- Teva Pharmaceutical Industries Limited, Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Teva Pharmaceutical Industries Limited's own proxy. As printed: 19,168,709. View filing ↗
- Jazz Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. View filing ↗
- United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
- Bausch Health Companies Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Bausch Health Companies Inc.'s own proxy. As printed: 16,877,326. View filing ↗
- Zimmer Biomet Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Zimmer Biomet Holdings Inc.'s own proxy. As printed: 16,106,550. View filing ↗
- Hologic, Inc., Section 10b CEO total. DEF 14A, filed 2025-01-16. CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. View filing ↗
- Organon & Co., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Organon & Co.'s own proxy. As printed: 15,813,296. View filing ↗
- Viatris Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Viatris Inc.'s own proxy. As printed: 15,273,331. View filing ↗
- Elanco Animal Health Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Elanco Animal Health Incorporated's own proxy. As printed: 14,925,756. View filing ↗
- Steris plc, Section 10b CEO total. DEF 14A, filed 2026-06-11. CEO total compensation as printed in Steris plc's own proxy. As printed: 11,508,522. View filing ↗
- Perrigo Company plc, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Perrigo Company plc's own proxy. As printed: 9,042,603. View filing ↗
- Section 10a, Elanco Animal Health Incorporated reciprocity. DEF 14A. Elanco Animal Health Incorporated names Bausch Health Companies Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Viatris Inc. reciprocity. DEF 14A. Viatris Inc. names Bausch Health Companies Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Perrigo Company plc reciprocity. DEF 14A. Perrigo Company plc names Bausch Health Companies Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗